Who are Drug: LYC-30937-EC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SINECATECHINS, PODOFILOX, POLIDEXIDE SULFATE, SUTILAINS, BNT162b4 10 mcg, qIRV (22/23).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/drug-lyc-30937-ec.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Drug: LYC-30937-EC — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug: LYC-30937-EC (Drug: LYC-30937-EC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Immunology.

phase 2 Immunomodulator Unknown Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Drug: LYC-30937-EC (Drug: LYC-30937-EC) — Lycera Corp.. LYC-30937-EC is an immunomodulatory drug.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Drug: LYC-30937-EC TARGET	Drug: LYC-30937-EC	Lycera Corp.	phase 2	Immunomodulator	Unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
BNT162b4 10 mcg	bnt162b4-10-mcg	Pfizer	marketed	Unknown	Unknown
qIRV (22/23)	qirv-22-23	Pfizer	marketed	Unknown	Unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (Immunomodulator class)

Actavis Mid-Atlantic LLC · 1 drug in this class
Active Biotech AB · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class
Bayer · 1 drug in this class
Beijing Children's Hospital · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
Chang Gung Memorial Hospital · 1 drug in this class
ALK-Abelló A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Drug: LYC-30937-EC — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-lyc-30937-ec. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab